Please do not leave this page until complete. This can take a few moments.
The co-founder of New Haven-based biotech Rallybio, who last week announced plans to resign as executive chairman at the end of the year, has been appointed to the board of another biotech firm in Stamford.
SpringWorks Therapeutics Inc., a commercial-stage biopharmaceutical company focused on cancer and severe rare diseases based at 100 Washington Blvd. in Stamford, announced Monday it has appointed Martin Mackay, to its board of directors.
Mackay is a co-founder of Rallybio, based at 234 Church St., in New Haven. The privately held company was incorporated in January 2018 as an early-stage biotechnology company developing therapies for patients with severe and rare diseases.
In an 8-K filing with the Securities and Exchange Commission last week, Rallybio said Mackay informed its board that “he will resign his executive chairman role and his employment with Rallybio, effective Dec. 31, 2024.”
After terminating his employment, Mackay will, however, remain on the board and serve as its chairman, the company said.
When Rallybio was founded, Mackay served as chief executive officer. He was succeeded as CEO on Aug. 1, 2023, by Dr. Stephen Uden, also a co-founder, who had been the company’s president and COO.
When Mackay left the CEO post, he became executive chairman of the board but remained a full-time employee and actively involved in the company, with a “focus on company strategy, investor relations and related activities,” the company said.
Rallybio said last week it expects Mackay to sign a consulting agreement with the company on Jan. 1, 2025. The agreement will allow Mackay to serve as a consultant to Rallybio until Jan. 1, 2026, though the consulting period could be extended upon mutual agreement or terminated by either party with 60 days’ notice.
Before co-founding Rallybio, Mackay had served as executive vice president, head of research and development, at Alexion from 2013-17.
He has more than 30 years of pharmaceutical and biotech R&D experience, which also includes leadership roles at Pfizer and AstraZeneca.
In addition to Rallybio and SpringWorks, Mackay also serves on the boards of Charles River Laboratories and Novo Nordisk.
The Hartford Business Journal 2025 Charity Event Guide is the annual resource publication highlighting the top charity events in 2025.
Learn moreHartford Business Journal provides the top coverage of news, trends, data, politics and personalities of the area’s business community. Get the news and information you need from the award-winning writers at HBJ. Don’t miss out - subscribe today.
SubscribeDelivering vital marketplace content and context to senior decision-makers throughout Connecticut ...
All Year Long!
The Hartford Business Journal 2025 Charity Event Guide is the annual resource publication highlighting the top charity events in 2025.
Hartford Business Journal provides the top coverage of news, trends, data, politics and personalities of the area’s business community. Get the news and information you need from the award-winning writers at HBJ. Don’t miss out - subscribe today.
Delivering vital marketplace content and context to senior decision-makers throughout Connecticut ...
All Year Long!
In order to use this feature, we need some information from you. You can also login or register for a free account.
By clicking submit you are agreeing to our cookie usage and Privacy Policy
Already have an account? Login
Already have an account? Login
Want to create an account? Register
In order to use this feature, we need some information from you. You can also login or register for a free account.
By clicking submit you are agreeing to our cookie usage and Privacy Policy
Already have an account? Login
Already have an account? Login
Want to create an account? Register
This website uses cookies to ensure you get the best experience on our website. Our privacy policy
To ensure the best experience on our website, articles cannot be read without allowing cookies. Please allow cookies to continue reading. Our privacy policy
0 Comments